David A Andrew

US Patent:

6488930, Dec 3, 2002

Filed:

Jan 15, 1999

Appl. No.:

09/231759

Inventors:

Lijun Wu - Reading MA
Nancy Ruffing - Somerville MA
David Andrew - Waltham MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39395

US Classification:

4241431, 5303882

Abstract:

The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR4 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.

US Patent:

6689570, Feb 10, 2004

Filed:

Sep 13, 2001

Appl. No.:

09/952385

Inventors:

David P. Andrew - Waltham MA
Brian A. Zabel - Dorchester MA
Paul D. Ponath - Boston MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

G01N 3353

US Classification:

435 724, 435 71, 435 72, 435 721, 435 723, 435 78, 530350, 530351, 5303871, 5303875, 5303879, 5303881, 5303882, 53038822, 53038873, 53038875, 5303891, 5303893

Abstract:

The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e. g. , TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e. g. , TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.

US Patent:

6884574, Apr 26, 2005

Filed:

Sep 28, 2001

Appl. No.:

09/966755

Inventors:

David P. Andrew - Waltham MA, US
Brian A. Zabel - Dorchester MA, US
Paul D. Ponath - Boston MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q001/00

US Classification:

435 4, 435 6, 435 71

Abstract:

The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e. g. , TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e. g. , TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.

US Patent:

6936248, Aug 30, 2005

Filed:

Mar 10, 2000

Appl. No.:

09/522752

Inventors:

David P. Andrew - Waltham MA, US
Brain A. Zabel - Stanford CA, US
Paul D. Ponath - San Francisco CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K039/40

US Classification:

4241431, 4241391, 435 71, 435 72, 435 721, 435 724, 435 29

Abstract:

The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e. g. , TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e. g. , TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.

US Patent:

7381412, Jun 3, 2008

Filed:

Apr 19, 2005

Appl. No.:

11/109349

Inventors:

David P. Andrew - Waltham MA, US
Brian A. Zabel - Stanford CA, US
Paul D. Ponath - San Francisco CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395

US Classification:

4241411, 4241301, 4241431, 435 71, 435326, 435332, 435334, 435 7021, 530350, 5303871, 5303881, 53038822

Abstract:

The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also relates to host cells that produce such antibodies or antigen-binding fragments, kits comprising such antibodies or antigen-binding fragments and methods of use for such antibodies and antigen-binding fragments.

US Patent:

7485301, Feb 3, 2009

Filed:

Oct 23, 2001

Appl. No.:

10/000759

Inventors:

David P. Andrew - Waltham MA, US
Brian A. Zabel - Stanford CA, US
Paul D. Ponath - San Francisco CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395

US Classification:

4241431, 4241331, 4241391, 514 2

Abstract:

The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e. g. , TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e. g. , TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.

US Patent:

63291592, Dec 11, 2001

Filed:

Mar 11, 1999

Appl. No.:

9/266464

Inventors:

David P. Andrew - Waltham MA
Brian A. Zabel - Dorchester MA
Paul D. Ponath - Boston MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39395
G01N 33563
G01N 3353
G01N 33566
G01N 33577

US Classification:

435 724

Abstract:

The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e. g. , TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e. g. , TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.